Enhancement of Adeno-Associated Virus-Mediated Gene Therapy Using Hydroxychloroquine in Murine and Human Tissues

Enhancement of Adeno-Associated Virus-Mediated Gene Therapy Using Hydroxychloroquine in Murine and Human Tissues

Bibliographic Details
Main Authors:	Laurel C. Chandler, Alun R. Barnard, Sarah L. Caddy, Maria I. Patrício, Michelle E. McClements, Howell Fu, Cristina Rada, Robert E. MacLaren, Kanmin Xue
Format:	Article
Language:	English
Published:	Elsevier 2023-03-01
Series:	Molecular Therapy: Methods & Clinical Development
Online Access:	http://www.sciencedirect.com/science/article/pii/S2329050123000037

Similar Items

Enhancement of adeno-associated viral (AAV) gene therapy using hydroxychloroquine in murine and human tissues
by: Chandler, L, et al.
Published: (2019)

Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy
by: Laurel C. Chandler, et al.
Published: (2020-07-01)

Immunomodulatory effects of hydroxychloroquine and chloroquine in viral infections and their potential application in retinal gene therapy
by: Chandler, L, et al.
Published: (2020)

Adeno-associated virus (AAV) dual vector strategies for gene therapy encoding large transgenes
by: McClements, M, et al.
Published: (2017)

Inclusion of the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances AAV2-Driven Transduction of Mouse and Human Retina
by: Maria I. Patrício, et al.
Published: (2017-03-01)

A fragmented adeno-associated viral dual vector strategy for treatment of diseases caused by mutations in large genes leads to expression of hybrid transcripts
by: McClements, M, et al.
Published: (2016)

Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina
by: Chandler, LC, et al.
Published: (2021)

Inclusion of the woodchuck hepatitis virus posttranscriptional regulatory element enhances AAV2-driven transduction of mouse and human retina
by: Patrício, M, et al.
Published: (2017)

RNA editing for Usher syndrome using CRISPR-Cas13
by: Fry, LE, et al.
Published: (2020)

Gene therapy for retinal disease.
by: McClements, M, et al.
Published: (2013)

CRISPR Manipulation of Age-Related Macular Degeneration Haplotypes in the Complement System: Potential Future Therapeutic Applications/Avenues
by: Ahmed Salman, et al.
Published: (2024-01-01)

CRISPR DNA Base Editing Strategies for Treating Retinitis Pigmentosa Caused by Mutations in <i>Rhodopsin</i>
by: Maria Kaukonen, et al.
Published: (2022-07-01)

CRISPR-Cas9 DNA Base-Editing and Prime-Editing
by: Ariel Kantor, et al.
Published: (2020-08-01)

A Review of CRISPR Tools for Treating Usher Syndrome: Applicability, Safety, Efficiency, and In Vivo Delivery
by: Lauren Major, et al.
Published: (2023-04-01)

Therapy Approaches for Stargardt Disease
by: Elena Piotter, et al.
Published: (2021-08-01)

New CRISPR Tools to Correct Pathogenic Mutations in Usher Syndrome
by: Lauren Major, et al.
Published: (2022-10-01)

Insights on the Regeneration Potential of Müller Glia in the Mammalian Retina
by: Ahmed Salman, et al.
Published: (2021-07-01)

RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences
by: Fry, LE, et al.
Published: (2020)

Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector.
by: Barnard, A, et al.
Published: (2014)

Cell-mediated inflammatory response to AAV gene therapy in the retina
by: Chandler, LC, et al.
Published: (2020)

Analysis of Early Cone Dysfunction in an In Vivo Model of Rod-Cone Dystrophy
by: Mark M. Hassall, et al.
Published: (2020-08-01)

Minicircle Delivery to the Neural Retina as a Gene Therapy Approach
by: Federica Staurenghi, et al.
Published: (2022-10-01)

Insights on the regeneration potential of Müller glia in the mammalian retina
by: Salman, A, et al.
Published: (2021)

Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases
by: Silja Hansen, et al.
Published: (2023-01-01)

Promoter orientation within an AAV-CRISPR vector affects Cas9 expression and gene editing efficiency
by: Fry, LE, et al.
Published: (2020)

Programmable RNA editing with endogenous ADAR enzymes – a feasible option for the treatment of inherited retinal disease?
by: Julia-Sophia Bellingrath, et al.
Published: (2023-05-01)

CRISPR Interference–Potential Application in Retinal Disease
by: Caroline F. Peddle, et al.
Published: (2020-03-01)

Accurate Quantification of AAV Vector Genomes by Quantitative PCR
by: Cristina Martinez-Fernandez de la Camara, et al.
Published: (2021-04-01)

Choroideremia: molecular mechanisms and development of AAV gene therapy
by: Patrício, M, et al.
Published: (2018)

Prenylation of rab6a as a potency assay for choroideremia gene therapy
by: Patricio, M, et al.
Published: (2017)

Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa
by: Orlans, HO, et al.
Published: (2021)

Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations
by: Ahmed Salman, et al.
Published: (2022-09-01)

In Silico Analysis of Pathogenic <i>CRB1</i> Single Nucleotide Variants and Their Amenability to Base Editing as a Potential Lead for Therapeutic Intervention
by: Julia-Sophia Bellingrath, et al.
Published: (2021-11-01)

Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?
by: Han, RC, et al.
Published: (2021)

Tetradecanoylphorbol-13-acetate (TPA) significantly increases AAV2/5 transduction of human neuronal cells in vitro
by: You, Q, et al.
Published: (2012)

In silico analysis of pathogenic CRB1 single nucleotide variants and their amenability to base editing as a potential lead for therapeutic intervention
by: Bellingrath, J-S, et al.
Published: (2021)

The biological activity of AAV vectors for choroideremia gene therapy can be measured by in vitro prenylation of RAB6A
by: Patrício, M, et al.
Published: (2018)

Envisioning the development of a CRISPR-Cas mediated base editing strategy for a patient with a novel pathogenic CRB1 single nucleotide variant
by: Bellingrath, J-S, et al.
Published: (2022)

Gene Therapies in Clinical Development to Treat Retinal Disorders
by: McClements, ME, et al.
Published: (2024)

Genome-editing strategies for treating human retinal degenerations
by: Quinn, J, et al.
Published: (2021)